Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat with Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma
NCT06294548Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of valemetostat in hepatocellular carcinoma (HCC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) up to 36 months and Phase II Efficacy up to 36 months. Started Jul 2025; status: recruiting.
02
Drugs
valemetostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06294548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294548.